Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the new standard therapy for many metastatic cancers. Development of anti-drug antibodies (ADAs) after treatment with other biopharmaceuticals has been thoroughly described, but the induction of ADAs...

Full description

Bibliographic Details
Main Authors: Anders H. Kverneland, Christian Enevold, Marco Donia, Lars Bastholt, Inge Marie Svane, Claus H. Nielsen
Format: Article
Language:English
Published: Taylor & Francis Group 2018-05-01
Series:OncoImmunology
Subjects:
ipilimumab
checkpoint inhibitors
immunogenicity
anti-drug antibodies
cancer
malignant melanoma
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1424674

Internet

http://dx.doi.org/10.1080/2162402X.2018.1424674

Similar Items